« Back to Record
Citation APA

Cappuzzo, F., Moreno Garcia, V., Ou, S.-H., Brandão, M., Sanmamed, M. F., Helissey, C., Wislez, M., Call, J., Grisanti, S., Johnson, M. D. L. M., Boni, V., Jamme, P., Monnet, I., Siena, S., Yan, C., Barasa, B., Richard, B., Joe, A., Laus, G., & Felip, E. (2023). 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC). Annals of oncology, 34, S1671. doi:10.1016/j.annonc.2023.10.595


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/401701

Cappuzzo, F., Moreno Garcia, V., Ou, S.-H., Brandão, M., Sanmamed, M. F., Helissey, C., Wislez, M., Call, J., Grisanti, S., Johnson, M. D. L. M., Boni, V., Jamme, P., Monnet, I., Siena, S., Yan, C., Barasa, B., Richard, B., Joe, A., Laus, G., & Felip, E. (2023). 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC). Annals of oncology, 34, S1671. doi:10.1016/j.annonc.2023.10.595